Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization

Int J Dermatol. 2001 Jul;40(7):481-4. doi: 10.1046/j.1365-4362.2001.01173-7.x.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • Acquired Immunodeficiency Syndrome / complications*
  • Adult
  • Antitubercular Agents / therapeutic use*
  • Desensitization, Immunologic / methods
  • Dose-Response Relationship, Drug
  • Ethambutol / therapeutic use
  • Female
  • Humans
  • Isoniazid / therapeutic use
  • Male
  • Pyrazinamide / therapeutic use
  • Rifampin / therapeutic use
  • Stevens-Johnson Syndrome / complications*
  • Treatment Outcome
  • Tuberculosis / complications
  • Tuberculosis / drug therapy*

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin